Isidora Tošić, Lisa N Heppler, Susana P Egusquiaguirre, Natalie Boehnke, Santiago Correa, Daniel F Costa, Elizabeth A Grossman Moore, Sharmistha Pal, Douglas S Richardson, Alexander R Ivanov, Daphne A Haas-Kogan, Daniel K Nomura, Paula T Hammond, David A Frank
The oncogenic transcription factor STAT3 is aberrantly activated in 70% of breast cancers, including nearly all triple-negative breast cancers (TNBC). Since STAT3 is difficult to target directly, we considered whether metabolic changes driven by activated STAT3 could provide a therapeutic opportunity. We found that STAT3 prominently modulated several lipid classes, with most profound effects on N-acyl taurine and arachidonic acid, both of which are involved in plasma membrane remodeling. To exploit these metabolic changes therapeutically, we screened a library of layer-by-layer (LbL) nanoparticles (NP) differing in the surface layer that modulates interactivity with the cell membrane...
February 3, 2021: Molecular Cancer Therapeutics